- Home
- SNEX vs TOVX Comparison
SNEX vs TOVX Comparison
Compare SNEX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNEX | TOVX |
|---|---|---|
| Founded | 1924 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 7.3M |
| IPO Year | 1994 | 2006 |
Fundamental Metrics
Financial Performance| Metric | SNEX | TOVX |
|---|---|---|
| Price | $98.80 | $0.21 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 396.5K | ★ 2.6M |
| Earning Date | 02-04-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.92 | N/A |
| EPS | ★ 5.89 | N/A |
| Revenue | ★ $130,897,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.74 | N/A |
| P/E Ratio | $16.49 | ★ N/A |
| Revenue Growth | ★ 32.62 | N/A |
| 52 Week Low | $60.58 | $0.19 |
| 52 Week High | $106.98 | $2.08 |
Technical Indicators
Market Signals| Indicator | SNEX | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 58.96 | 40.70 |
| Support Level | $91.30 | $0.21 |
| Resistance Level | $100.78 | $0.24 |
| Average True Range (ATR) | 3.27 | 0.03 |
| MACD | 1.01 | 0.00 |
| Stochastic Oscillator | 76.26 | 18.41 |
Price Performance
Historical ComparisonAbout SNEX StoneX Group Inc.
StoneX Group Inc is a Global brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, Global payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.